Navigation Links
AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:11/17/2010

mpany, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at (877) 547-6340, and at Prospectus_Department@Jefferies.com.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Forward Looking Statements

Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, may be forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. These statements include, but are not limited to, AVANIR's ability to successfully market and sell NUEDEXTA in the United States, the safety and efficacy of NUEDEXTA, and the anticipated timing and success of the commercial launch of NUEDEXTA. Risks that could cause actual results to differ include the occurrence of adverse safety events with NUEDEXTA, our limited capital resources, our dependence on third parties for manufacturing and distribution of NUEDEXTA, that we may not adequately build or maintain the necessary sales, marketing, supply chain management and reimbursement capabilities on our own or enter into arrangements with third parties to perform these functions in a timely manner or on acceptable terms, and other risks that are described in further detail in the offering prospectus and in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to time in other publicly availa
'/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
2. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
3. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
4. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
5. Nautilus Neurosciences and Tribute Pharmaceuticals Announce Exclusive Canadian License for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine
6. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
7. Vanda Pharmaceuticals Appoints Chief Financial Officer
8. Jazz Pharmaceuticals Announces Presentation at the Lazard Capital Markets Healthcare Conference on November 17
9. Transcept Pharmaceuticals Reports Third Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
11. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Pressure ... "Company") and Parabase Genomics ("Parabase"), (together "the ... a strategic research and development agreement (the ... PBI will develop a front-end, sample preparation ... and newborn confirmatory testing process. The sample ...
(Date:7/22/2014)... July 22, 2014  NeuroSigma, Inc. (NeuroSigma), a ... commercialization of its non-invasive Monarch ™ eTNS™ ... disorders, today announced that enrollment has begun in a ... (eTNS) as adjunctive therapy for the treatment of Lennox-Gastaut ... at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... , July 22, 2014 ... umfassenden Schutz von Pharmazeuten und Krankenpflegern ... Equashield ( http://www.equashield.com ), ... System Transfer Devices, CSTDs) für gefährliche Medikamente, ernannte ... und Hersteller von medizinischen Produkten, zu seinem ...
Breaking Medicine Technology:Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
... Turn the Tide on Antibiotic-Resistant InfectionsPRINCETON, N.J., March ... and the Plexus Institute (Plexus) today announce results ... Staphylococcus aureus (MRSA) prevention program that employed ... and behavioral change, to trigger significant reductions in ...
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
Cached Medicine Technology:CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 2CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 3CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5
(Date:7/22/2014)... (PRWEB) July 22, 2014 DocbookMD ... process of deploying one of the largest physician-centric mobile ... ( MHMD ) in Houston. , Created by Austin-based ... the DocbookMD application will be embedded into MHMD’s Accountable ... searched for the best technology to put this capability ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Dr. Dental is ... existing patients and new visitors in mind, one of the ... and visual layout that makes navigation very easy. Dr. Dental ... experience of going to the dentist affordable, convenient and fun, ... helpful new feature is an appointment scheduling system right on ...
(Date:7/22/2014)... 22, 2014 A Florida woman has ... that alleges the death of her husband was the ... thinner, Bernstein Liebhard LLP reports. According to her complaint, ... for the Southern District of Florida on June 23rd, ... suffered a subdural hemorrhage the following June. Despite emergency ...
(Date:7/22/2014)... Among women undergoing a minimally invasive hysterectomy using electric ... 10,000 women at the time of the procedure, according ... has been concern that this procedure, in which the ... the spread of undetected malignancies. , Despite the commercial ... estimates of the prevalence of malignancy at the time ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 2Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 3Health News:Memorial Hermann Physician Network Launches Physician Mobile Communication Solution Throughout Houston 4Health News:Dr. Dental Reveals Exciting New Website 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Study examines presence of uterine cancers at the time of hysterectomy using morcellation 2Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... , ... ... ... ...
... Research (AADR) has announced David C. Johnsen, dean of the ... the 2010 AADR Jack Hein Public Service Award. This award ... Meeting & Exhibition in Washington, DC, March 3, 2010. ... Institutes of Health and the National Institute of Dental and ...
... American Association for Dental Research (AADR) has announced Irwin D. ... York, as the recipient of the inaugural 2010 AADR Distinguished ... Annual Meeting & Exhibition in Washington, DC, March 3, 2010. ... in 1946, and gave up his part-time private practice in ...
... study suggests , FRIDAY, Feb. 19 (HealthDay News) -- In ... have identified a defective signaling pathway that contributes to the ... thick, sticky mucus to build up in the lungs and ... lethal genetic diseases in children and young adults. , In ...
... ... ... ... ...
... ... in the Ambulatory EHR space , ... (PRWEB) February 19, 2010 -- CapSite™ has announced the release of the 2010 U.S. ... the Health Information Technology for Economic and Clinical Health (HITECH) component of the American Recovery ...
Cached Medicine News:Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 2Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 3Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 4Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 5Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 6Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 7Health News:Figure Skating Standards Foster Eating Disorders, Says Kimberly Dennis, M.D. 8Health News:Drug Improved Survival in Mice With Cystic Fibrosis 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 2Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 3Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 4Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 5Health News:Jim Huber to Serve as National Spokesman for 'Know Your Score: Fight Prostate Campaign' at Myrtle Beach Golf Holiday in August 6Health News:CapSite Announces Release of the 2010 U.S. Ambulatory EHR Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: